Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Mirum Pharmaceuticals, Inc. (MIRM) had Stock-Based Compensation of $15.80M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$111.58M |
|
$-14.68M |
|
$23.02M |
|
$88.57M |
|
$126.77M |
|
$-15.18M |
|
$1.53M |
|
$-13.65M |
|
$-13.65M |
|
$-14.68M |
|
$-14.68M |
|
$-14.68M |
|
$-14.68M |
|
$-15.18M |
|
$-8.70M |
|
48.89M |
|
48.89M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$410.82M |
|
$1.11M |
|
$279.43M |
|
$690.25M |
|
$127.58M |
|
$308.51M |
|
$329.41M |
|
$456.99M |
|
$233.26M |
|
$-10.59M |
|
$233.26M |
|
49.45M |
|
| Cash Flow Statement Financials | |
$-1.96M |
|
$-16.13M |
|
$6.36M |
|
$222.93M |
|
$212.25M |
|
$-10.68M |
|
|
Stock-Based Compensation |
$15.80M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.22 |
|
-- |
|
-- |
|
0.57 |
|
1.32 |
|
79.37% |
|
-13.61% |
|
-13.61% |
|
-- |
|
-12.23% |
|
-13.15% |
|
$-2.00M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
1.03 |
|
1.16 |
|
77.31 |
|
-6.29% |
|
138.61% |
|
-2.13% |
|
-2.71% |
|
$4.72 |
|
$-0.04 |
|
$-0.04 |
|